Regenerative medicine aims to use our body's own resources to regenerate tissues and recover damaged functions.
In this product line BTI has been a world pioneer in developing the first technology described in scientific literature to obtain 100% autologous (from the patient him- or herself) plasma rich in growth factors.
Due to the excellent results in treatment a large number of public figures and elite sportsmen and women have turned to Endoret® technology with the aim of improved recovery in as little time as possible from either an injury or surgery.
What is Endoret®(PRGF®) technology?
It is a biomedical technology patented by BTI which, from a minimal volume of the patient's blood, allows the isolation and concentration of growth factors and other proteins responsible for the reparation and regeneration of tissue to be used in treatment. Through this, the application of Endoret® allows the repair process of tissue damaged during injury to be stimulated, speeded up and improved.
Growth factors are proteins which carry out an essential role in tissue repair and regeneration processes as they set off the chain reaction of biological effects such as cell proliferation and differentiation, blood vessel generation (angiogenesis) and cell migration to areas where regeneration is required (chemotaxis). No exogenic agent can govern all these processes so effectively.
Endoret® is the most advanced autologous system for Platelet Rich Plasma and has been endorsed for both its efficiency in stimulating and accelerating tissue regeneration as well as for its biosafety, having been published in over a hundred scientific papers in specialised journals, and has been presented at hundreds of national and international congresses.
One of Endoret® technology's standout features is the possibility of obtaining up to 5 different formulations that are biocompatible based on the processing of the patient's own blood:
Supernatant: Ideal for use as eye drops.
Liquid: For infiltration in muscle, tendon, joint and subcutaneous injuries, etc. Also used to bioactivate BTI dental implant surfaces and for prostheses used in orthopaedics.
Coagulant or “Scaffold”: Coagulation formulation which allows interior retention of platelets and growth factors, as well as other bioactive molecules with the possibility of being used in surgery and dermal lesions.
Fibrin membrane: This enables the balanced and gradual release of growth factors and other proteins. Due to its homoeostatic properties it is an excellent biomaterial for sealing bone defects or stimulating the post-extraction alveolus and epithelisation, as well as for many other applications.
Graft: Endoret® can be used bound with cells, autologous or heterologous biomaterials, as it is an excellent vehicle that provides important clinical advantages.
This great versatility increases the therapeutic possibilities of this biomedical technology and allows tailored clinical solutions.